Loading...
Loading...
- Shares of Twist Bioscience Corp TWST fell after the firm issued fiscal second-quarter revenue guidance that fell below the consensus Wall Street estimate.
- For Q1 FY23, Twist posted a 29% increase in sales to $54.2 million, almost in line with the consensus of $54.1 million.
- The company shipped approximately 134,000 genes during the quarter to 2,060 customers, compared to about 1,800 customers during the year-ago quarter.
- For Q1, the company reported an EPS loss of $(0.74), down from $(0.91) a year ago compared to the consensus of $(1.13).
- Guidance: Twist Bioscience expects fiscal Q2 revenues of $56.5 million, below the consensus of $61.9 million, with $24 million in synbio revenues, $25 million in next-generation sequencing revenues, and biopharma revenues of $7.5 million.
- It anticipates full-year fiscal 2023 revenue of $261 million to $269 million, which remains unchanged.
- Price Action: TWST shares are down 16.6% at $25.77 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in